Accumulated Clinical Experiences from Successful Treatment of 1377 Severe and Critically Ill COVID-19 Cases

Curr Med Sci. 2020 Aug;40(4):597-601. doi: 10.1007/s11596-020-2221-1. Epub 2020 Aug 29.

Abstract

In late December 2019, COVID-19 was firstly recognized in Wuhan, China and spread rapidly to all of the provinces of China. The West Campus of Wuhan Union Hospital, the designated hospital to admit and treat the severe and critically ill COVID-19 cases, has treated a large number of such patients with great success and obtained lots of valuable experiences based on the Chinese guideline (V7.0). To standardize and share the treatment procedures of severe and critically ill cases, Wuhan Union Hospital has established a working group and formulated an operational recommendation, including the monitoring, early warning indicators, and several treatment principles for severe and critically ill cases. The treatment experiences may provide some constructive suggestions for treating the severe and critically ill COVID-19 cases all over the world.

Keywords: 2019-nCoV; COVID-19; guidelines; pneumonia; treatment.

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Anticoagulants / therapeutic use
  • Antiviral Agents / therapeutic use
  • Betacoronavirus*
  • COVID-19
  • COVID-19 Drug Treatment
  • COVID-19 Serotherapy
  • COVID-19 Testing
  • China / epidemiology
  • Clinical Laboratory Techniques
  • Combined Modality Therapy
  • Comorbidity
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / therapy*
  • Critical Illness
  • Dexamethasone / therapeutic use
  • Hospitals
  • Humans
  • Immunization, Passive
  • Medicine, Chinese Traditional
  • Pandemics
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / therapy*
  • Respiratory Therapy / methods
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal, Humanized
  • Anticoagulants
  • Antiviral Agents
  • Dexamethasone
  • tocilizumab